Clarivate (NYSE:CLVT) Issues FY 2026 Earnings Guidance

Clarivate (NYSE:CLVT) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 0.700-0.800 for the period, compared to the consensus EPS estimate of 0.620. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.4 billion.

Clarivate Price Performance

Shares of Clarivate stock opened at $1.68 on Tuesday. The firm has a market cap of $1.11 billion, a P/E ratio of -2.94 and a beta of 1.51. The firm’s 50-day simple moving average is $2.82 and its 200-day simple moving average is $3.48. Clarivate has a twelve month low of $1.66 and a twelve month high of $4.91. The company has a debt-to-equity ratio of 0.90, a quick ratio of 0.87 and a current ratio of 0.87.

Clarivate (NYSE:CLVT) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.04. The firm had revenue of $617.00 million during the quarter, compared to analyst estimates of $604.79 million. Clarivate had a negative net margin of 15.83% and a positive return on equity of 8.55%. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. As a group, research analysts expect that Clarivate will post 0.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on CLVT. Weiss Ratings restated a “sell (e+)” rating on shares of Clarivate in a research report on Monday, December 29th. The Goldman Sachs Group cut shares of Clarivate from a “buy” rating to a “neutral” rating and cut their target price for the company from $4.20 to $3.60 in a research note on Thursday, January 8th. Morgan Stanley restated an “underweight” rating and set a $3.00 price target (down from $5.00) on shares of Clarivate in a research report on Wednesday, December 17th. Finally, Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Three investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Clarivate presently has a consensus rating of “Reduce” and a consensus price target of $3.70.

Insider Buying and Selling

In other news, insider Bar Veinstein sold 309,902 shares of Clarivate stock in a transaction on Monday, December 1st. The stock was sold at an average price of $3.74, for a total value of $1,159,033.48. Following the completion of the sale, the insider directly owned 848,811 shares of the company’s stock, valued at approximately $3,174,553.14. This trade represents a 26.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 23.18% of the company’s stock.

Institutional Trading of Clarivate

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jump Financial LLC acquired a new position in Clarivate during the 4th quarter valued at about $41,000. PharVision Advisers LLC bought a new stake in shares of Clarivate during the third quarter worth approximately $45,000. Pitcairn Co. acquired a new position in Clarivate in the second quarter valued at approximately $52,000. RPO LLC bought a new position in Clarivate in the fourth quarter valued at approximately $64,000. Finally, Corsair Capital Management L.P. bought a new position in Clarivate in the fourth quarter valued at approximately $67,000. 85.72% of the stock is currently owned by institutional investors and hedge funds.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.